iLite anti-CD20 ADCC Activity Set


The Eagle Biosciences iLite Assay Ready Cells are designed for the specific detection of drug potency in serum/plasma as well as neutralizing antibodies in serum/plasma. They utilize an assay technique called reporter gene assay ( RPG ) to analyze serum/plasma samples. The reporter genes utilized are encoded with a bioluminescent luciferase (Firefly luciferase). Different levels of luminescence detected from each reporter gene cell indicates different levels of their expression. The iLite® anti-CD20 ADCC Activity Set is for research use only.

iLite anti-CD20 ADCC Activity Set

For Research Use Only

Incubation Time: 4 hours
Fold Induction: 150 fold
EC50: 2 ng/mL
LLOQ: 1 pg/mL

The Eagle Biosciences iLite® anti-CD20 ADCC Activity Set includes (components are also sold separately):

Key benefits of iLite® ADCC Activity Assays

  • Unparalleled sensitivity
  • High serum tolerance
  • Normalization read-out included
  • Negative control available for screening of unspecific activity
  • Easy to use – no culturing required on target or effector cells

Product Developed and Manufactured by Svar Life Science

Additional Information


The launch of iLite® Assay Ready Cells targeting anti-CD20 antibody development, brings the first four products from EuroDiagnostica’s ADCC product line to market and showcases the unique set-up of the iLite system. The iLite ADCC anti-CD20 assay has got a turnaround time of less than 5 hours and has got sensitivity in the pg/mL area, and includes many of the other iLite features, such as normalization, serum tolerance and low lot-to-lot variation.

Measuring the ability of a drug to induce antibody-dependent cell-mediated cytotoxicity (ADCC) in a straight forward, sensitive and reproducible manner, is a key aspect in development and manufacturing of antibody-based therapeutics. The iLite ADCC Activity Assay, unique in its set-up, includes ADCC Effector Assay Ready Cells and matched Target Assay Ready Cells, engineered to work optimally together and give unparalleled sensitivity. A negative control cell line is also available for each target, allowing screening for unspecific activation of ADCC, giving added value to each experiment.

FIGURE 1: The interaction between the reporter gene Effector cell and the Target cell, generated by the crosslinking via a specific drug antibody. The resulting luminescence originates exclusively from this crosslinking and the signaling from the CD16 receptor to the Firefly Luciferase.

FIGURE 2: When the Target cell have been depleted for the specific surface target molecule, the crosslinking between the Effector and the Target cell cannot be established and hence no luminescence from Firefly Luciferase is generated. But luminescence from NanoLuc, which is expressed under a constitutive promotor, is still present.

Frequently Asked Questions


Product Manual